Algert Global LLC Buys 8,891 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

Algert Global LLC lifted its holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 12.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 82,793 shares of the biopharmaceutical company's stock after acquiring an additional 8,891 shares during the quarter. Algert Global LLC owned approximately 0.09% of Ultragenyx Pharmaceutical worth $3,483,000 at the end of the most recent reporting period.

A number of other large investors have also bought and sold shares of the business. Wilmington Savings Fund Society FSB bought a new position in shares of Ultragenyx Pharmaceutical in the third quarter valued at about $83,000. Nordea Investment Management AB raised its position in Ultragenyx Pharmaceutical by 8.9% in the 4th quarter. Nordea Investment Management AB now owns 39,673 shares of the biopharmaceutical company's stock worth $1,658,000 after purchasing an additional 3,246 shares during the last quarter. Wealth Enhancement Advisory Services LLC lifted its holdings in Ultragenyx Pharmaceutical by 1.4% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 22,047 shares of the biopharmaceutical company's stock worth $928,000 after buying an additional 294 shares in the last quarter. KBC Group NV lifted its holdings in Ultragenyx Pharmaceutical by 2,275.8% during the 4th quarter. KBC Group NV now owns 61,010 shares of the biopharmaceutical company's stock worth $2,567,000 after buying an additional 58,442 shares in the last quarter. Finally, R Squared Ltd acquired a new stake in shares of Ultragenyx Pharmaceutical in the 4th quarter valued at $103,000. 97.67% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on RARE. Canaccord Genuity Group raised their price target on Ultragenyx Pharmaceutical from $121.00 to $136.00 and gave the company a "buy" rating in a report on Tuesday, February 18th. Morgan Stanley upped their target price on shares of Ultragenyx Pharmaceutical from $64.00 to $65.00 and gave the company an "overweight" rating in a research note on Friday. JPMorgan Chase & Co. raised their target price on shares of Ultragenyx Pharmaceutical from $104.00 to $117.00 and gave the stock an "overweight" rating in a report on Thursday, March 27th. HC Wainwright reiterated a "buy" rating and set a $95.00 price objective on shares of Ultragenyx Pharmaceutical in a report on Friday, February 14th. Finally, Piper Sandler decreased their price objective on Ultragenyx Pharmaceutical from $140.00 to $115.00 and set an "overweight" rating for the company in a report on Monday, March 17th. One investment analyst has rated the stock with a hold rating and fourteen have issued a buy rating to the company. According to MarketBeat.com, Ultragenyx Pharmaceutical has an average rating of "Moderate Buy" and an average price target of $90.93.

Ultragenyx Pharmaceutical Price Performance

Ultragenyx Pharmaceutical stock traded down $0.82 during mid-day trading on Friday, reaching $35.16. 1,136,694 shares of the company were exchanged, compared to its average volume of 824,723. The company has a fifty day simple moving average of $36.89 and a 200-day simple moving average of $42.55. The firm has a market cap of $3.30 billion, a PE ratio of -5.55 and a beta of 0.34. Ultragenyx Pharmaceutical Inc. has a 12 month low of $29.59 and a 12 month high of $60.37.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last released its earnings results on Tuesday, May 6th. The biopharmaceutical company reported ($1.57) EPS for the quarter, missing the consensus estimate of ($1.54) by ($0.03). The firm had revenue of $139.29 million during the quarter, compared to the consensus estimate of $145.98 million. Ultragenyx Pharmaceutical had a negative net margin of 101.60% and a negative return on equity of 193.80%. Ultragenyx Pharmaceutical's quarterly revenue was up 28.0% compared to the same quarter last year. During the same period in the prior year, the business earned ($2.03) earnings per share. Sell-side analysts anticipate that Ultragenyx Pharmaceutical Inc. will post -5.18 earnings per share for the current year.

Insider Buying and Selling at Ultragenyx Pharmaceutical

In related news, EVP Karah Herdman Parschauer sold 2,990 shares of the stock in a transaction that occurred on Thursday, February 27th. The shares were sold at an average price of $42.88, for a total value of $128,211.20. Following the completion of the transaction, the executive vice president now owns 54,991 shares of the company's stock, valued at $2,358,014.08. This represents a 5.16 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Emil D. Kakkis sold 73,434 shares of the business's stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $42.10, for a total transaction of $3,091,571.40. Following the sale, the chief executive officer now directly owns 641,731 shares in the company, valued at approximately $27,016,875.10. The trade was a 10.27 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 125,405 shares of company stock valued at $5,285,169. 5.50% of the stock is currently owned by corporate insiders.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.